Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, 3000, Australia.
EJ Whitten Prostate Cancer Research Centre at Epworth, Melbourne, 3121, Australia.
Future Oncol. 2021 Jun;17(17):2225-2241. doi: 10.2217/fon-2020-1293. Epub 2021 Mar 16.
Prostate-specific membrane antigen (PSMA) PET/CT is a novel imaging technique for the detection and staging of either primary or recurrent prostate cancer. Early studies demonstrated its improved sensitivity and specificity over and in combination with other currently employed imaging techniques, such as multiparametric MRI, bone scan, PET and CT. However, the lack of strength and confidence in these studies has meant incorporation of PSMA PET/CT into clinical guidelines and practice has been limited to date. In response, a number of high-quality prospective studies have recently emerged and reflect exciting results seen in preceding publications. Here we recount some of the key earlier publications, report results from the latest studies and look to the future discussing some of the eagerly awaited ongoing clinical trials.
前列腺特异膜抗原（PSMA）PET/CT 是一种用于检测和分期原发性或复发性前列腺癌的新型成像技术。早期研究表明，它的敏感性和特异性均优于其他目前使用的成像技术（如多参数 MRI、骨扫描、PET 和 CT），并且与这些技术联合应用时效果更佳。然而，由于这些研究的力度和可信度不足，迄今为止，PSMA PET/CT 仅被纳入临床指南，并未广泛应用于临床实践。为此，最近出现了一些高质量的前瞻性研究，这些研究反映了之前发表的文献中令人振奋的结果。在此，我们回顾了一些早期的重要文献，报告了最新研究的结果，并探讨了一些正在进行的备受期待的临床试验。
